Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TCRX
STRONG SELLTScan Therapeutics, Inc. · Healthcare · United States · $52M · Avg Vol: $656K/d
4
StockRankGet insider-trade alerts
Q
13
V
37
M
20
P/E (TTM)
—
ROE
-80.9%
D/E
1.0x
Dividend %
—
Loading 1Y...
PRICE (1Y)-15.8%
SMA 50SMA 200
Close
$0.768
RSI (14)
31.7
52W High
$2.57
From 52W High
0.3%
SCORE BREAKDOWN
Quality
13
ROIC
-57.8%13.2
ROE
-80.9%11.1
GP/Assets
-41.8%1.8
Op. Margin
-2967.3%4.6
FCF/Assets
-54.6%5.0
Piotroski
111.4
Int. Cover
-43.7x13.4
D/E Ratio
0.95x15.2
Current Ratio
6.65x78.8
Value
37
P/E (TTM)
—N/A
EV/EBITDA
-0.1x25.0
P/FCF
—N/A
P/B
0.5x97.1
P/S
5.7x38.1
Div Yield
—N/A
Momentum
20
52W High %
30%7.8
RS 6M
-40%21.4
SMA 50/200
0.84x27.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+8%26.6
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$52M
P/E (Forward)
-0.9x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TCRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TCRX | TScan Therapeutics, Inc.(you) | $52M | 4 | STRONG SELL |
| ATYR | aTyr Pharma, Inc. | $52M | 5 | STRONG SELL |
| ESLA | Estrella Immunopharma, Inc. | $62M | 2 | STRONG SELL |
| INKT | MiNK Therapeutics, Inc. | $55M | 8 | STRONG SELL |
| CRDF | Cardiff Oncology, Inc. | $64M | 2 | STRONG SELL |
| 2257.HK | Sirnaomics Ltd. | $64M | 1 | STRONG SELL |
| DWTX | Dogwood Therapeutics, Inc. | $50M | 10 | STRONG SELL |
| RNTX | Rein Therapeutics Inc. | $68M | 2 | STRONG SELL |
| CNTX | Context Therapeutics Inc. | $56M | 10 | STRONG SELL |
| TIL | Instil Bio, Inc. | $50M | 11 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%